Onco-Innovations Enhances Leadership with Key Appointments

Onco-Innovations Limited has announced the appointment of Dr. Islam Mohamed as Chief Medical Officer and Stephen M. Novak as Chief of Research and Development. These additions aim to bolster the company's capabilities as it advances its lead product candidate, ONC010, toward human trials. The shift from preclinical development to clinical stage is a pivotal moment for the company.

Dr. Mohamed brings extensive experience in clinical medicine and drug development. He will oversee clinical strategy and regulatory engagements, focusing on the PNKP Inhibitor Technology Program. Novak, with over 25 years of experience, will manage development operations and partnerships crucial for the transition to clinical milestones.

The appointments are part of Onco-Innovations' strategic plan to strengthen its team and accelerate progress in oncology therapeutics. The company's aim is to align with best practices in drug development and regulatory compliance while maintaining effective partnerships with key industry players. These moves reflect a commitment to innovation and long-term shareholder value.